UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
4mNpr6
4mNpr6
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Presentations<br />
Association of mammographic density measures and<br />
breast cancer ‘intrinsic’ molecular subtypes<br />
Authors*: Aaron D. Norman, Rulla M. Tamimi, Christopher G. Scoe, Kimberly A. Bertrand, Matthew R. Jensen,<br />
Daniel W. Visscher, Fergus J. Couch, John Shepherd, Bo Fan, Yunn-Yi Chen, Lin Ma, Andrew Beck,<br />
Vernon S. Pankratz, Karla Kerlikowske, Celine M. Vachon<br />
Pres #: 2593 Section: 36 Presentation Date/Time: Monday, April 18: 1:00-5:00PM<br />
Location:<br />
Presentation Type: Poster Session<br />
Kerlikowski Lab Expertise: My lab focuses on breast imaging and the epidemiology of invasive breast cancer,<br />
DCIS and breast density, and risk prediction models for invasive breast cancer. We have developed cohorts<br />
of women at risk for invasive breast cancer and DCIS and developed comprehensive databases that include<br />
breast imaging, pathologic, clinical, biomarker, and risk factor data, as well as follow-up for subsequent<br />
disease and death.<br />
http://cancer.ucsf.edu/people/profiles/kerlikowske_karla.3457<br />
__________________________________________________________________________<br />
Common genetic variants associated with breast cancer risk used<br />
in the Athena study to enhance models identifying women for<br />
breast cancer chemoprevention<br />
Authors*: Sarah Theiner, Sarah D. Sawyer, Paige Kendall, Alexandra S. Perry, Denise Wolf, Scott Huntsman,<br />
Bo Pan, Jeffery A. Tice, David A. Pearce, Thomas Cink, Laura Esserman, Elad Ziv, Laura van ‘t Veer<br />
Pres #: 2623 Section: 37 Presentation Date/Time: Monday, April 18: 1:00-5:00PM<br />
Location:<br />
Presentation Type: Poster Session<br />
van ‘t Veer Lab Expertise: Dr. van ’t Veer’s research focuses on personalized medicine & advancing patient<br />
management based on knowledge of the genetic makeup of the tumor as well as the genetic makeup of the<br />
patient. Her laboratory investigates human kinases & how kinase inhibitors elicit response & resistance, which<br />
is also utilized to understand agent efficacy in the I-SPY 2 TRIAL. She is the PI of the Athena Breast Health<br />
Network, a 150,000 women cohort study evaluating new paradigms to enhance breast health. She leads the<br />
targeted genome testing of 100,000 women for 9 breast cancer susceptibility genes and a selection of ~100<br />
known susceptibility SNPs. She is one of the PIs for the NIH Big Data to Knowledge Center Translational<br />
Genomics, facilitating worldwide standardization of sharing annotated genomics data.<br />
http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358<br />
*<strong>UCSF</strong> authors in bold<br />
26
Change language